Colin Hislop
Chief Tech/Sci/R&D Officer bij EIGER BIOPHARMACEUTICALS, INC.
Profiel
Currently, Colin Hislop is Senior VP-Clinical & Development Operations at Eiger BioPharmaceuticals, Inc.
In his past career he was Chief Medical Officer & Senior Vice President at Anthera Pharmaceuticals, Inc., Principal at Eli Lilly & Co., Manager-Clinical Development at Procter & Gamble Co., Vice President-Clinical Development at CV Therapeutics, Inc., Vice President-Clinical Development at Peninsula Pharmaceuticals, Inc. and Chief Development Officer for Versartis, Inc.
Dr. Hislop received an undergraduate degree from the University of Surrey and a doctorate from the University of London.
Actieve functies van Colin Hislop
Bedrijven | Functie | Begin |
---|---|---|
EIGER BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Colin Hislop
Bedrijven | Functie | Einde |
---|---|---|
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Chief Tech/Sci/R&D Officer | 05-09-2017 |
ANTHERA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-04-2016 |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Chief Tech/Sci/R&D Officer | 01-06-2005 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Chief Tech/Sci/R&D Officer | 01-09-2004 |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Opleiding van Colin Hislop
University of London | Doctorate Degree |
University of Surrey | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
ANTHERA PHARMACEUTICALS, INC. | Health Technology |
EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Peninsula Pharmaceuticals, Inc.
Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Commercial Services |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |